Close Menu

Philips

The Swiss firm said that it will use the cash to accelerate development and validation of the first version of its forthcoming molecular diagnostics platform, which will incorporate nucleic acid sample prep technology recently acquired from Royal Philips Electronics.

The platform features new nucleic acid sample prep and amplification technologies and will be developed for a wide range of DNA and RNA molecular diagnostic testing, including in oncology and infectious diseases, according to a Biocartis executive.

The deal is the latest for Philips, which is increasingly looking for partners to bring applications to market on its internally developed biosensor and microarray platforms.

BioArray Briefs: 2009.03.03

Premium

Febit, READNA Consortium, US Department of Agriculture, Autogenomics, Oxford Gene Technology, Optra, Gene Logic, Genstruct, Global Biomarker Conference

The research, published online Sunday in Nature Nanotechnology, is the first to show that scientists can detect unlabeled single DNA bases "to a confidence level … appropriate for a highly competitive commercial sequencing system," Oxford Nanopore's CEO said.

Pages

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.